Your session is about to expire
← Back to Search
Regorafenib for Adenoid Cystic Carcinoma
Study Summary
This trial will help researchers learn if regorafenib is a safe and effective treatment option for adenoid cystic carcinoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 1 & 2 trial • 495 Patients • NCT02024607Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not taking strong medication inhibitors or inducers like rifampin or ketoconazole.I do not have any serious heart conditions.I am not on any cancer treatments except for bone metastases medication.I have not had major surgery or a significant injury in the last 28 days.I have untreated heart artery disease.I am on medication for heart rhythm problems not managed by beta blockers or digoxin.I have HIV or hepatitis B/C that needs antiviral treatment.I have a wound or ulcer that hasn’t healed, but it’s not caused by cancer.I have had an organ transplant.I am not pregnant or breast-feeding.I haven't had a stroke, clot, or embolism in the last 6 months.I have had cancer before, but it won't affect this trial.I have previously taken regorafenib.I am not using any herbal remedies like St. John's wort.My cancer has returned or spread and cannot be removed by surgery or cured with radiation.I can take care of myself but might not be able to do active work.It's been over 2 weeks since my last cancer treatment, and I've recovered from the side effects.I have a history of bleeding disorders.I require dialysis for kidney failure.I am on medication for seizures.I have a condition that affects how my body absorbs nutrients.I can swallow and keep down pills.My blood, liver, and kidney tests are within normal ranges.I am receiving radiation for symptom relief, not to cure my cancer.I am 18 years old or older.My amylase and creatinine levels are within normal limits.My heart condition is not severe and is classified below NYHA Class III.My scans show new or worsening cancer spots within the last 6 months.I agree to a biopsy unless it's deemed too risky or unnecessary by a doctor.I have a tumor that can be measured with scans.I currently have symptoms of interstitial lung disease.My liver function tests are within the required range.My blood counts meet the required levels without transfusions.I have not had severe bleeding in the last 4 weeks.I do not have an infection that would stop me from receiving the study treatment.My high blood pressure is not controlled even with medication.My cancer is confirmed as adenoid cystic carcinoma, even if it didn't start in the salivary glands.I have been diagnosed with phaeochromocytoma.I am not pregnant and have taken a test in the last 2 weeks to confirm this, or I am post-menopausal or surgically sterilized.I have not had a heart attack or unstable chest pain recently.I do not have symptoms from brain or spinal cord tumor spread.My blood thinner medication is stable and monitored if it's a Vitamin-K antagonist.
- Group 1: patients with adenoid cystic carcinoma
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
At what number of sites is this clinical experiment being conducted?
"At present, this experimental trial is recruiting participants from 5 different sites. Those who are interested may be able to find a site in Basking Ridge, Rockville Centre, or Commack which would reduce the need for extensive travel if they choose to participate."
What therapeutic application is Regorafenib most commonly employed for?
"Those who have been given anti-vegf treatments may gain relief from regorafenib, which is also an effective tool to manage advanced directives, sorafenib, and unresectable gastrointestinal stromal tumors."
Has the U.S. Food & Drug Administration certified Regorafenib?
"Regorafenib's safety rating measures a 2, signifying that there is supportive data on its safety but not yet any research-backed evidence of efficacy."
What conclusions have been drawn from prior experiments involving Regorafenib?
"Memorial Sloan Kettering Cancer Center initiated the first clinical trial of regorafenib in 2014, and since then there have been 82 completed studies. Currently, 58 more trials are underway with a majority being conducted out of Basking Ridge, New jersey."
Is this the pioneering endeavor of its sort?
"Research into Regorafenib was initiated in 2014, with the first clinical trial backed by Bayer. After successful completion of Phase 1 and 2 trials involving 38 patients respectively, it has been granted approval for use in medication today. Currently there are 58 active research studies spanning 418 cities across 30 countries researching its efficacy."
Is there room for additional participants in the experiment?
"Unfortunately, this particular clinical trial has stopped accepting applications. It was first published on March 1st 2014 and last edited April 26th 2022. If you're still looking for research studies, there are presently 2470 trials in search of participants with carcinoma or adenoid cystic issues; 58 studies actively recruiting patients to test Regorafenib as well."
How many participants is the clinical trial recruiting?
"Unfortunately, this study is no longer searching for participants. The trial first appeared on March 1st 2014 and was updated most recently on April 26th 2022. If you are seeking other clinical trials related to carcinoma, adenoid cystic or Regorafenib specifically there are 2470 active studies recruiting patients and 58 enrolment programmes involving the latter medication."
Share this study with friends
Copy Link
Messenger